Loading clinical trials...
Loading clinical trials...
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination With Tremelimumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Conditions
Interventions
MEDI4736 monotherapy
tremelimumab+MEDI4736
Locations
21
United States
Research Site
Tampa, Florida, United States
Research Site
New York, New York, United States
Research Site
Vancouver, British Columbia, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Start Date
November 16, 2015
Primary Completion Date
June 15, 2017
Completion Date
June 15, 2017
Last Updated
August 2, 2018
NCT02600949
NCT06904378
NCT06445062
NCT07165951
NCT07096362
NCT06168812
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions